Making TMB Relevant in the Clinic: Best Practices for TMB Calculation, Reporting, and Interpretation
Albrecht Stenzinger, M.D.
Jonathan Nowak, M.D.,Ph.D.
This webinar is a recorded presentation of a live broadcast and includes the presentation, handout, and the audience QA.
Please note that this content was created in 2019. In the time since this material was posted, there may have been additional developments, advancements, and/or more current publications in this field.
AMP Education is constantly updating our educational offerings, and will remove or replace content that is no longer accurate. Please be sure to use the search function to find related or updated material available in our catalogue at educate.amp.org. The Training and Education Committee works with AMP Education Programs to bring you the most up-to-date and cutting-edge information on molecular pathology research, applications, and training.
Approaches to calculating, reporting, and interpreting Tumor Mutational Burden (TMB) testing will be discussed in this second of two updates on the broader use of TMB as a potentially prognostic and predictive tool in clinical care. Dr. Stenzinger will provide an overview of how large-scale efforts to harmonize TMB measurement may bolster the potential clinical utility of TMB reporting.
- Discuss the current state of TMB calculation and reporting as well as efforts to standardize this process across laboratories.
- Understand the potential clinical utility of TMB and how it should be interpreted especially in the context of other immunotherapy biomarkers.
- Harness available information to improve implementation of molecularly targeted cancer diagnostics and therapies in the clinical setting.
Recording Date: August 15, 2019
Duration: 1 hr
Level of Instruction: Basic
CME/CMLE credit: 1.00 hour
CE Credit for this course has expired.
How to claim credit:
To earn CME/CMLE credit, all learners must watch the webinar and then complete the online survey.
AMA PRA Category 1 Credit(s)™
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of American Society for Clinical Pathology (ASCP) and Association for Molecular Pathology (AMP). The American Society for Clinical Pathology (ASCP) is accredited by the ACCME to provide continuing medical education for physicians.
The ASCP designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology for 1.0 hours of CMLE credit. ASCP CMLE credit hours are acceptable for the ASCP Board of Certification (BOC) Certification Maintenance Program (CMP). CMLE credit hours meet the continuing education requirements for the ASCP Board of Certification Credential Maintenance Program (CMP) and state relicensure requirements for laboratory personnel. Participants should claim only the credit commensurate with the extent of their participation in the activity.
For more information on this series, please go here.
This program has been supported through an educational grant from Bristol-Myers Squibb.
AMP is pleased to collaborate in the Immunotherapy Collaborative of Oncology Networked Communities, IC-ONC. IC-ONC is a global information network in which multidisciplinary healthcare providers, responsible for treating patients with cancer, are connected via education.
Please be sure to visit www.ic-onc.org to learn more about the collaborative and all it has to offer.
Note: Members of AMP can access many of the webinars at no cost or a deep discount. Join the AMP Family!
All sales are final. No refunds will be issued.
No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.